Skyrizi 180 mg/1.2mL
risankizumab-rzaa · INJECTION · AbbVie Inc.
No Recall History
Plain English
Skyrizi is a injection containing risankizumab-rzaa at 180 mg/1.2mL, taken subcutaneous. Manufactured by AbbVie Inc..
Key Facts
- Brand Name
- Skyrizi
- Generic Name
- risankizumab-rzaa
- NDC Code (Product)
0074-8300- Manufacturer
- AbbVie Inc.
- Strength
- 180 mg/1.2mL
- Dosage Form
- INJECTION
- Route
- SUBCUTANEOUS
- Marketing Status
- Application #
- BLA761105
- Drug Class
- Interleukin-23 Antagonist [EPC]
- Marketing Start
- 09/03/2025
Recall History
No Recall HistoryFrequently Asked Questions
What is Skyrizi used for?
Skyrizi contains risankizumab-rzaa. It is a injection taken subcutaneous. Consult your doctor for specific uses.
Is Skyrizi a controlled substance?
Skyrizi is not classified as a controlled substance by the DEA.
What is the generic name for Skyrizi?
The generic name for Skyrizi is risankizumab-rzaa. There are no other listed brand versions of risankizumab-rzaa.
What is the NDC code for Skyrizi 180 mg/1.2mL?
The NDC (National Drug Code) for Skyrizi 180 mg/1.2mL is 0074-8300, listed by AbbVie Inc..
Not medical advice. Always consult your doctor or pharmacist before making any medication decisions.
Data from openFDA · Public domain (CC0 1.0)